Trial Profile
Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2013
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions
- 03 Oct 2013 New trial record
- 26 Sep 2013 Results have been published in Vaccine, according to a Medicines and Healthcare products Regulatory Agency (MHRA) media release.